The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Anti-Nuclear Radiation Drug Market Research Report 2024

Global Anti-Nuclear Radiation Drug Market Research Report 2024

Publishing Date : Sep, 2023

License Type :
 

Report Code : 1794395

No of Pages : 120

Synopsis
Nuclear radiation refers to the various microscopic particles and electromagnetic radiation or energy released during nuclear reactions such as fission and decay of atomic nuclei. This kind of radioactive material exists in large quantities in nuclear explosions, nuclear leakage accidents and nuclear waste. Anti-nuclear radiation drugs commonly used in clinical practice include thiol drugs, cytokine drugs, hormone drugs, metal complexing agents, and Chinese herbal medicines.
Global Anti-Nuclear Radiation Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-Nuclear Radiation Drug market research.
The development prospect of anti-nuclear radiation medicine depends to a large extent on the development trend of global nuclear energy. If the global nuclear power generation continues to increase, the market demand for nuclear radiation protection drugs may increase accordingly.
At present, the global anti-nuclear radiation drug market has been researched and developed by some major pharmaceutical companies and biotechnology companies. The main types of anti-nuclear radiation drugs include stable iodine, Prussian blue, zinc lozenges, complement activators, antibiotics, anti-radiation drugs, etc. Among them, stable iodine and Prussian blue are the most commonly used drugs for the prevention and treatment of acute radiation exposure.
Although the market size of nuclear radiation protection drugs is relatively small, it is expected to maintain rapid growth in the coming years. This is primarily attributable to heightened concern over nuclear radiation incidents and increased need for prevention and treatment of radiation exposure.
However, the development and application of anti-nuclear radiation drugs still face some challenges. For example, anti-nuclear radiation drugs currently on the market are mainly aimed at a specific type or dose of radiation, rather than being widely applicable. In addition, due to the rarity of nuclear radiation incidents, there are certain difficulties in clinical trials and applications of these drugs.
In general, the development prospects of anti-nuclear radiation drugs seem bright, but continued in-depth research and development are needed to overcome existing technical and market challenges.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Anti-Nuclear Radiation Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Amgen
Humanwell Healthcare
Jiangsu Wuzhong Pharmaceutical Group
Hisun Pharmaceutical
Beijing Centergate Technologies
Lisheng Pharmaceutical
Bayer AG
GlaxoSmithKline
Pfizer
Onconova
Novartis AG
Teva Pharmaceuticals
Clinigen
Sun Pharmaceutical
Taj Pharmaceuticals
Merro Pharmaceutical
Luye Pharma
Mingren Pharma
Gilead Sciences
Johnson & Johnson
Merck KGaA
Genentech Inc.
Segment by Type
Potassium Iodide (KI)
Prussian Blue
Diethylenetriamine Pentaacetate (DTPA)
Filgrastim
Amifostine
Ex-Rad
Segment by Sales Channel
Online Sales
Offline Sales
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-Nuclear Radiation Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Sales Channel)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Sales Channel Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index
1 Anti-Nuclear Radiation Drug Market Overview
1.1 Product Overview and Scope of Anti-Nuclear Radiation Drug
1.2 Anti-Nuclear Radiation Drug Segment by Type
1.2.1 Global Anti-Nuclear Radiation Drug Market Value Comparison by Type (2023-2029)
1.2.2 Potassium Iodide (KI)
1.2.3 Prussian Blue
1.2.4 Diethylenetriamine Pentaacetate (DTPA)
1.2.5 Filgrastim
1.2.6 Amifostine
1.2.7 Ex-Rad
1.3 Anti-Nuclear Radiation Drug Segment by Sales Channel
1.3.1 Global Anti-Nuclear Radiation Drug Market Value by Sales Channel: (2023-2029)
1.3.2 Online Sales
1.3.3 Offline Sales
1.4 Global Anti-Nuclear Radiation Drug Market Size Estimates and Forecasts
1.4.1 Global Anti-Nuclear Radiation Drug Revenue 2018-2029
1.4.2 Global Anti-Nuclear Radiation Drug Sales 2018-2029
1.4.3 Global Anti-Nuclear Radiation Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-Nuclear Radiation Drug Market Competition by Manufacturers
2.1 Global Anti-Nuclear Radiation Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Anti-Nuclear Radiation Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Anti-Nuclear Radiation Drug Average Price by Manufacturers (2018-2023)
2.4 Global Anti-Nuclear Radiation Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-Nuclear Radiation Drug, Product Type & Application
2.7 Anti-Nuclear Radiation Drug Market Competitive Situation and Trends
2.7.1 Anti-Nuclear Radiation Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-Nuclear Radiation Drug Players Market Share by Revenue
2.7.3 Global Anti-Nuclear Radiation Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Nuclear Radiation Drug Retrospective Market Scenario by Region
3.1 Global Anti-Nuclear Radiation Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-Nuclear Radiation Drug Global Anti-Nuclear Radiation Drug Sales by Region: 2018-2029
3.2.1 Global Anti-Nuclear Radiation Drug Sales by Region: 2018-2023
3.2.2 Global Anti-Nuclear Radiation Drug Sales by Region: 2024-2029
3.3 Global Anti-Nuclear Radiation Drug Global Anti-Nuclear Radiation Drug Revenue by Region: 2018-2029
3.3.1 Global Anti-Nuclear Radiation Drug Revenue by Region: 2018-2023
3.3.2 Global Anti-Nuclear Radiation Drug Revenue by Region: 2024-2029
3.4 North America Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.4.1 North America Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.4.3 North America Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.5.1 Europe Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.5.3 Europe Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.7.1 Latin America Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.7.3 Latin America Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-Nuclear Radiation Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-Nuclear Radiation Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-Nuclear Radiation Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-Nuclear Radiation Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-Nuclear Radiation Drug Sales by Type (2018-2029)
4.1.1 Global Anti-Nuclear Radiation Drug Sales by Type (2018-2023)
4.1.2 Global Anti-Nuclear Radiation Drug Sales by Type (2024-2029)
4.1.3 Global Anti-Nuclear Radiation Drug Sales Market Share by Type (2018-2029)
4.2 Global Anti-Nuclear Radiation Drug Revenue by Type (2018-2029)
4.2.1 Global Anti-Nuclear Radiation Drug Revenue by Type (2018-2023)
4.2.2 Global Anti-Nuclear Radiation Drug Revenue by Type (2024-2029)
4.2.3 Global Anti-Nuclear Radiation Drug Revenue Market Share by Type (2018-2029)
4.3 Global Anti-Nuclear Radiation Drug Price by Type (2018-2029)
5 Segment by Sales Channel
5.1 Global Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2029)
5.1.1 Global Anti-Nuclear Radiation Drug Sales by Sales Channel (2018-2023)
5.1.2 Global Anti-Nuclear Radiation Drug Sales by Sales Channel (2024-2029)
5.1.3 Global Anti-Nuclear Radiation Drug Sales Market Share by Sales Channel (2018-2029)
5.2 Global Anti-Nuclear Radiation Drug Revenue by Sales Channel (2018-2029)
5.2.1 Global Anti-Nuclear Radiation Drug Revenue by Sales Channel (2018-2023)
5.2.2 Global Anti-Nuclear Radiation Drug Revenue by Sales Channel (2024-2029)
5.2.3 Global Anti-Nuclear Radiation Drug Revenue Market Share by Sales Channel (2018-2029)
5.3 Global Anti-Nuclear Radiation Drug Price by Sales Channel (2018-2029)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Amgen Anti-Nuclear Radiation Drug Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Humanwell Healthcare
6.2.1 Humanwell Healthcare Corporation Information
6.2.2 Humanwell Healthcare Description and Business Overview
6.2.3 Humanwell Healthcare Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Humanwell Healthcare Anti-Nuclear Radiation Drug Product Portfolio
6.2.5 Humanwell Healthcare Recent Developments/Updates
6.3 Jiangsu Wuzhong Pharmaceutical Group
6.3.1 Jiangsu Wuzhong Pharmaceutical Group Corporation Information
6.3.2 Jiangsu Wuzhong Pharmaceutical Group Description and Business Overview
6.3.3 Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Jiangsu Wuzhong Pharmaceutical Group Anti-Nuclear Radiation Drug Product Portfolio
6.3.5 Jiangsu Wuzhong Pharmaceutical Group Recent Developments/Updates
6.4 Hisun Pharmaceutical
6.4.1 Hisun Pharmaceutical Corporation Information
6.4.2 Hisun Pharmaceutical Description and Business Overview
6.4.3 Hisun Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hisun Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.4.5 Hisun Pharmaceutical Recent Developments/Updates
6.5 Beijing Centergate Technologies
6.5.1 Beijing Centergate Technologies Corporation Information
6.5.2 Beijing Centergate Technologies Description and Business Overview
6.5.3 Beijing Centergate Technologies Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Beijing Centergate Technologies Anti-Nuclear Radiation Drug Product Portfolio
6.5.5 Beijing Centergate Technologies Recent Developments/Updates
6.6 Lisheng Pharmaceutical
6.6.1 Lisheng Pharmaceutical Corporation Information
6.6.2 Lisheng Pharmaceutical Description and Business Overview
6.6.3 Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Lisheng Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.6.5 Lisheng Pharmaceutical Recent Developments/Updates
6.7 Bayer AG
6.6.1 Bayer AG Corporation Information
6.6.2 Bayer AG Description and Business Overview
6.6.3 Bayer AG Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer AG Anti-Nuclear Radiation Drug Product Portfolio
6.7.5 Bayer AG Recent Developments/Updates
6.8 GlaxoSmithKline
6.8.1 GlaxoSmithKline Corporation Information
6.8.2 GlaxoSmithKline Description and Business Overview
6.8.3 GlaxoSmithKline Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 GlaxoSmithKline Anti-Nuclear Radiation Drug Product Portfolio
6.8.5 GlaxoSmithKline Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Pfizer Anti-Nuclear Radiation Drug Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Onconova
6.10.1 Onconova Corporation Information
6.10.2 Onconova Description and Business Overview
6.10.3 Onconova Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Onconova Anti-Nuclear Radiation Drug Product Portfolio
6.10.5 Onconova Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Corporation Information
6.11.2 Novartis AG Anti-Nuclear Radiation Drug Description and Business Overview
6.11.3 Novartis AG Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Novartis AG Anti-Nuclear Radiation Drug Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 Teva Pharmaceuticals
6.12.1 Teva Pharmaceuticals Corporation Information
6.12.2 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Description and Business Overview
6.12.3 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Teva Pharmaceuticals Anti-Nuclear Radiation Drug Product Portfolio
6.12.5 Teva Pharmaceuticals Recent Developments/Updates
6.13 Clinigen
6.13.1 Clinigen Corporation Information
6.13.2 Clinigen Anti-Nuclear Radiation Drug Description and Business Overview
6.13.3 Clinigen Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Clinigen Anti-Nuclear Radiation Drug Product Portfolio
6.13.5 Clinigen Recent Developments/Updates
6.14 Sun Pharmaceutical
6.14.1 Sun Pharmaceutical Corporation Information
6.14.2 Sun Pharmaceutical Anti-Nuclear Radiation Drug Description and Business Overview
6.14.3 Sun Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Sun Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.14.5 Sun Pharmaceutical Recent Developments/Updates
6.15 Taj Pharmaceuticals
6.15.1 Taj Pharmaceuticals Corporation Information
6.15.2 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Description and Business Overview
6.15.3 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Taj Pharmaceuticals Anti-Nuclear Radiation Drug Product Portfolio
6.15.5 Taj Pharmaceuticals Recent Developments/Updates
6.16 Merro Pharmaceutical
6.16.1 Merro Pharmaceutical Corporation Information
6.16.2 Merro Pharmaceutical Anti-Nuclear Radiation Drug Description and Business Overview
6.16.3 Merro Pharmaceutical Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Merro Pharmaceutical Anti-Nuclear Radiation Drug Product Portfolio
6.16.5 Merro Pharmaceutical Recent Developments/Updates
6.17 Luye Pharma
6.17.1 Luye Pharma Corporation Information
6.17.2 Luye Pharma Anti-Nuclear Radiation Drug Description and Business Overview
6.17.3 Luye Pharma Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Luye Pharma Anti-Nuclear Radiation Drug Product Portfolio
6.17.5 Luye Pharma Recent Developments/Updates
6.18 Mingren Pharma
6.18.1 Mingren Pharma Corporation Information
6.18.2 Mingren Pharma Anti-Nuclear Radiation Drug Description and Business Overview
6.18.3 Mingren Pharma Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Mingren Pharma Anti-Nuclear Radiation Drug Product Portfolio
6.18.5 Mingren Pharma Recent Developments/Updates
6.19 Gilead Sciences
6.19.1 Gilead Sciences Corporation Information
6.19.2 Gilead Sciences Anti-Nuclear Radiation Drug Description and Business Overview
6.19.3 Gilead Sciences Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Gilead Sciences Anti-Nuclear Radiation Drug Product Portfolio
6.19.5 Gilead Sciences Recent Developments/Updates
6.20 Johnson & Johnson
6.20.1 Johnson & Johnson Corporation Information
6.20.2 Johnson & Johnson Anti-Nuclear Radiation Drug Description and Business Overview
6.20.3 Johnson & Johnson Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Johnson & Johnson Anti-Nuclear Radiation Drug Product Portfolio
6.20.5 Johnson & Johnson Recent Developments/Updates
6.21 Merck KGaA
6.21.1 Merck KGaA Corporation Information
6.21.2 Merck KGaA Anti-Nuclear Radiation Drug Description and Business Overview
6.21.3 Merck KGaA Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Merck KGaA Anti-Nuclear Radiation Drug Product Portfolio
6.21.5 Merck KGaA Recent Developments/Updates
6.22 Genentech Inc.
6.22.1 Genentech Inc. Corporation Information
6.22.2 Genentech Inc. Anti-Nuclear Radiation Drug Description and Business Overview
6.22.3 Genentech Inc. Anti-Nuclear Radiation Drug Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Genentech Inc. Anti-Nuclear Radiation Drug Product Portfolio
6.22.5 Genentech Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-Nuclear Radiation Drug Industry Chain Analysis
7.2 Anti-Nuclear Radiation Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-Nuclear Radiation Drug Production Mode & Process
7.4 Anti-Nuclear Radiation Drug Sales and Marketing
7.4.1 Anti-Nuclear Radiation Drug Sales Channels
7.4.2 Anti-Nuclear Radiation Drug Distributors
7.5 Anti-Nuclear Radiation Drug Customers
8 Anti-Nuclear Radiation Drug Market Dynamics
8.1 Anti-Nuclear Radiation Drug Industry Trends
8.2 Anti-Nuclear Radiation Drug Market Drivers
8.3 Anti-Nuclear Radiation Drug Market Challenges
8.4 Anti-Nuclear Radiation Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’